Cite
HARVARD Citation
Smit, E. et al. (2019). Pembrolizumab for all PD-L1-positive NSCLC. Lancet. 393 (10183), pp. 1776-1778. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Smit, E. et al. (2019). Pembrolizumab for all PD-L1-positive NSCLC. Lancet. 393 (10183), pp. 1776-1778. [Online].